Novartis stock ends week at EUR 127.97 with EUR 128.88 high
Published on 10/10/2026 at 10:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Novartis stock was EUR 127.97 in weekend trading on October 10, 2026.
- The observed weekly range was EUR 124.61 to EUR 128.88.
- Novartis announced FDA approval of Rhapsido for symptomatic dermographism on October 7, 2026.
Market context: Market report SMI.
Novartis stock was EUR 127.97 in weekend trading at Lang & Schwarz at 10:42 a.m. CEST on October 10, 2026, unchanged versus the EUR 127.97 close at Lang & Schwarz on October 9, 2026.
Weekend trading
Lang & Schwarz listed a bid of EUR 127.66 and an ask of EUR 128.28 at 10:42 a.m. CEST on October 10, 2026. The observed weekly range was EUR 124.61 to EUR 128.88. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.
The week in figures
The weekend-trading price was EUR 127.97 against the EUR 127.97 close at Lang & Schwarz on October 9, 2026. The observed range stood between EUR 124.61 and EUR 128.88.
Chronology of the week
On October 7, 2026, Novartis announced that the U.S. Food and Drug Administration approved Rhapsido, or remibrutinib, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. The company said 29.3 percent of patients achieved a complete hive response at Week 12, compared with 14.0 percent for placebo, in the Phase III RemIND trial. The details were published in an Novartis release.
Also on October 7, 2026, Novartis said it would present 46 abstracts from its multiple sclerosis portfolio at MSToronto2026, including late-breaking Phase III REMODEL-1 and REMODEL-2 data on remibrutinib. The announcement was distributed by GlobeNewswire.
Dates of the coming week
The next Xetra session is dated October 12, 2026. Novartis also lists multiple sclerosis presentations for October 21, October 22, and October 23, 2026.
